Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by and welcome. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Anne-Marie Fields, Managing Director at PrecisionAQ. Please go ahead. Thank you, Operator. Good morning, and welcome to Selectar Bioscience's second quarter 2025 Financial Results and Business Update conference call. Joining us today from Selectar are Jim Caruso, President and CEO, who will provide an overview of the company's progress, before turning the call over to Chad Coley and CFO for a financial review of the quarter. Following this, Jared Lancourt, Chief Operating Officer, will give an update on the company's progress and plans for its promising clinical pipeline of radiopharmaceuticals. Selectar issued a press release earlier this morning detailing the content of today's call. A copy can be found on the investor page of Selectar's corporate website. I want to remind callers that the information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's and in our FEC filing. The content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, August 14, 2025. The company undertakes no ob...